S Arnardottir1, K Borg, T Ansved. 1. Department of Clinical Neuroscience, Division of Neurology, Karolinska Hospital, Stockholm, Sweden. snjolaug.arnardottir@ks.se
Abstract
OBJECTIVE: To characterise morphological abnormalities in relation to muscle fibre type in sporadic inclusion body myositis (s-IBM). METHODS: 14 muscle biopsies from 11 patients with s-IBM were characterised for morphological abnormalities and fibre type composition as well as muscle fibre regeneration and cytoskeletal structure, using histochemical and immunohistochemical techniques. RESULTS: Morphological abnormalities included inflammatory infiltrates and "rimmed vacuoles," and pronounced variation in fibre size. There were no significant differences in fibre type composition between s-IBM patients and controls based on the myofibrillar ATPase staining. A differential effect on muscle fibre sizes was noted, type II fibres being smaller in the s-IBM patients than in the controls. Conversely, the mean type I muscle fibre diameter in the s-IBM patients was larger than in the controls, though this difference was not significant. An ongoing intense regeneration process was present in s-IBM muscle, as indicated by the expression of neonatal myosin heavy chain, vimentin, and CD56 (Leu-19) in most of the muscle fibres. The cytoskeletal proteins dystrophin and desmin were normally expressed in s-IBM muscle fibres that were not undergoing degeneration or regeneration. CONCLUSIONS: There are extensive morphological and morphometric alterations in s-IBM, affecting different muscle fibre types in different ways. The cytoskeletal structure of type I and II muscle fibres remains unaffected in different stages of the disease.
OBJECTIVE: To characterise morphological abnormalities in relation to muscle fibre type in sporadic inclusion body myositis (s-IBM). METHODS: 14 muscle biopsies from 11 patients with s-IBM were characterised for morphological abnormalities and fibre type composition as well as muscle fibre regeneration and cytoskeletal structure, using histochemical and immunohistochemical techniques. RESULTS:Morphological abnormalities included inflammatory infiltrates and "rimmed vacuoles," and pronounced variation in fibre size. There were no significant differences in fibre type composition between s-IBM patients and controls based on the myofibrillar ATPase staining. A differential effect on muscle fibre sizes was noted, type II fibres being smaller in the s-IBM patients than in the controls. Conversely, the mean type I muscle fibre diameter in the s-IBM patients was larger than in the controls, though this difference was not significant. An ongoing intense regeneration process was present in s-IBM muscle, as indicated by the expression of neonatal myosin heavy chain, vimentin, and CD56 (Leu-19) in most of the muscle fibres. The cytoskeletal proteins dystrophin and desmin were normally expressed in s-IBM muscle fibres that were not undergoing degeneration or regeneration. CONCLUSIONS: There are extensive morphological and morphometric alterations in s-IBM, affecting different muscle fibre types in different ways. The cytoskeletal structure of type I and II muscle fibres remains unaffected in different stages of the disease.
Authors: Karla Punkt; Matthias Fritzsche; Christoph Stockmar; Pierre Hepp; Christoph Josten; Maren Wellner; Stefan Schering; Igor B Buchwalow Journal: Histochem Cell Biol Date: 2005-11-16 Impact factor: 4.304
Authors: Kenneth C Parker; Sek Won Kong; Ronan J Walsh; Mohammad Salajegheh; Behzad Moghadaszadeh; Anthony A Amato; Remedios Nazareno; Yin Yin Lin; Bryan Krastins; David A Sarracino; Alan H Beggs; Jack L Pinkus; Steven A Greenberg Journal: Muscle Nerve Date: 2009-06 Impact factor: 3.217
Authors: Yue-Bei Luo; Chalermchai Mitrpant; Russell Johnsen; Vicki Fabian; Merrilee Needham; Sue Fletcher; Steve D Wilton; Frank L Mastaglia Journal: Int J Clin Exp Pathol Date: 2013-08-15
Authors: Julia V Wanschitz; Odile Dubourg; Emmanuelle Lacene; Michael B Fischer; Romana Höftberger; Herbert Budka; Norma B Romero; Bruno Eymard; Serge Herson; Gillian S Butler-Browne; Thomas Voit; Olivier Benveniste Journal: Neuromuscul Disord Date: 2012-10-09 Impact factor: 4.296